Blog
RSS FeedPosted by Michael Wonder on 12 Mar 2025
Zolbetuximab in combination with chemotherapy for the first-line treatment of adults with claudin-18.2 positive, HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma (final guidance)
12 March 2025 - NICE has published final evidence-based recommendations on the use of zolbetuximab (Vyloy) in combination with chemotherapy ...
Posted by Michael Wonder on 12 Mar 2025
Natalizumab for the treatment of patients with highly active relapsing–remitting multiple sclerosis after disease-modifying therapy
12 March 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 08 Mar 2025
Vertex announces UK MHRA approval of Alyftrek (deutivacaftor/tezacaftor/vanzacaftor), a once daily next in class CFTR modulator for the treatment of cystic fibrosis
7 March 2025 - In head to head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and further decreased sweat chloride ...
Posted by Michael Wonder on 07 Mar 2025
Lazertinib approved for use in combination with amivantamab for the treatment of adults with non-small cell lung cancer
6 March 2025 - The MHRA has today approved lazertinib (Lazcluze) for adults with non-small cell lung cancer that has spread ...
Posted by Michael Wonder on 07 Mar 2025
Amivantamab in combination with pemetrexed disodium heptahydrate and carboplatin for the treatment of patients with advanced EGFR exon 20 insertion mutation positive non-small-cell lung cancer
6 March 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 07 Mar 2025
Second consultation launched on NHS funding for Alzheimer's treatments
6 March 2025 - Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab. ...
Posted by Michael Wonder on 06 Mar 2025
Cemiplimab in combination with platinum-based chemotherapy for the treatment of patients with advanced non-small-cell lung cancer
5 March 2025 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 06 Mar 2025
Idebenone for the treatment of patients 12 years of age and older with visual impairment in Leber’s hereditary optic neuropathy (updated draft guidance)
5 March 2025 - NICE has produced additional draft guidance on the use of idebenone in the NHS in England. ...
Posted by Michael Wonder on 05 Mar 2025
Sparsentan for the treatment of patients with primary IgA nephropathy
4 March 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 02 Mar 2025
mRESVIA RSV vaccine approved to protect patients aged 60 and over
28 February 2025 - A study found that around 4 months after vaccination, people who received the respiratory syncytial virus vaccine had ...
Posted by Michael Wonder on 26 Feb 2025
Exagamglogene autotemcel for the treatment of patients with severe sickle cell disease
26 February 2025 - NICE has published final evidence-based recommendations on the use of exagamglogene autotemcel (Casgevy) for the treatment ...
Posted by Michael Wonder on 26 Feb 2025
Osimertinib mesylate for the adjuvant treatment of patients with EGFR mutation positive non-small-cell lung cancer after complete tumour resection (final guidance)
26 February 2025 - NICE has published final evidence-based recommendations on the use of osimertinib mesylate (Tagrisso) for the adjuvant ...
Posted by Michael Wonder on 21 Feb 2025
Green light for groundbreaking personalised cancer therapy that reprogrammes immune system
20 February 2025 - Final guidance published today recommends lisocabtagene maraleucel (Breyanzi; Bristol Myers Squibb) as an option for treating ...
Posted by Michael Wonder on 21 Feb 2025
Use of surrogate endpoints in health technology assessment: a review of selected NICE technology appraisals in oncology
19 February 2025 - Surrogate endpoints, used to substitute for and predict final clinical outcomes, are increasingly being used to support ...
Posted by Michael Wonder on 19 Feb 2025
Selpercatinib for the treatment of patients with advanced RET fusion positive non-small-cell lung cancer
19 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...